With the Supreme Court set to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., key questions are coming into focus. How might the Court's decision reshape strategies for brand-name and generic manufacturers? And what risks will companies face when marketing “skinny label” products?
A new policy brief from the Eira Initiative, "The Economics of Skinny Labels," explores these issues -- and examines what’s at stake for patients, generic manufacturers, innovators, and policymakers.
The bottom line: The best path forward preserves timely generic entry while maintaining strong incentives for post-approval innovation.
Eira Initiative